Biobank Study for Patients with Chronic Inflammatory Rheumatism and Osteoporosis at Toulouse University Hospital

What this Trial Is About

This research aims to create a biobank for patients with chronic inflammatory rheumatism, including rheumatoid arthritis RA, spondyloarthritis SpA, and psoriatic arthritis PsA, as well as those with osteoporosis. The goal is to identify biomarkers linked to how well patients respond to treatments, helping doctors make better treatment choices. The study is observational and sponsored by the University Hospital of Toulouse. Participants include patients beginning new biologic or targeted synthetic disease-modifying anti-rheumatic drugs bDMARDs and tsDMARDs for their conditions, as well as those with osteoporosis starting anti-osteoporotic treatments. Blood samples will be collected to study potential biomarkers. This biobank will support research on treatment response and disease severity. Participants will provide blood samples during the study. Researchers will measure treatment response using the European League Against Rheumatism EULAR response criteria after three months. The study involves follow-up to track biomarkers and treatment outcomes. The total participation period and specific visit schedules vary according to patient treatment and condition.

Biobank for Inflammatory Chronic Diseases and Osteoporosis